In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

It was more so, as Francis reflects, because he believed, after weighing the risks and opportunity, that Teva, a company today of 37,000 employees with operations in more than 33 countries, had the ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

However, the company's share price opened nearly 10% lower on the NYSE due to a disappointing 2025 outlook. Teva has also provided guidance on 2025 for the first time. The company forecasts 2025 ...

Shares of Teva Pharmaceutical Industries ( TEVA -2.29%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.01%) and Nasdaq ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total sales are derived from generics and off-patent branded drugs. Generic drugs ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Teva Pharmaceutical Industries Ltd. (TEVA ... some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance ...